Effect of Prevalence of BMI on Efficacy of Herbal Medicines in Girls' Sexual Precocity (NCT04665713) | Clinical Trial Compass
CompletedNot Applicable
Effect of Prevalence of BMI on Efficacy of Herbal Medicines in Girls' Sexual Precocity
China192 participantsStarted 2020-12-18
Plain-language summary
Effect of Prevalence of Overweight and Obesity(Body Mass Index (BMI)) on Efficacy of herbal medicines(ZiYinXieHuo) in girls sexual Precocity
Who can participate
Age range4 Years – 8 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
\- no abnormal weight and height in parents and families, no organic diseases, no drugs affecting gonadal axis or obesity; normal health, no secondary obesity caused by endocrine and genetic metabolic diseases, no lifestyle intervention to treat obesity.
Exclusion Criteria:
\- central neoplastic lesions, rare syndrome, severe heart, liver and kidney diseases and other chronic diseases such as tuberculosis, asthma, rheumatism, complicated infection, congenital hypothyroidism associated with precocious puberty, peripheral precocious puberty, incomplete precocious puberty and so on.
What they're measuring
1
Bone Age
Timeframe: From enrollment to the sixth month after treatment